<DOC>
	<DOCNO>NCT01177501</DOCNO>
	<brief_summary>The early relapse ovarian cancer occur within 6 month chemotherapy include platinum regimen call relapse 'platinum resistant ' consecutively patient die quickly disease . For relapse occur 6 12 month , recommendation occur study conduct . Therefore seem interesting develop research intensive chemotherapy use combination carboplatin ( drug widely use ovarian cancer ) Topotecan , use high dose protocol . Topotecan demonstrate efficacy relapse ovarian cancer possible use high dos , recent study ( ITOV01 ) demonstrate feasibility dose escalation topotecan monotherapy ( MTD set 9 mg / m² / dx 5 day ) . This project feasibility research combination topotecan carboplatin high dose escalation protocol early ovarian cancer relapse occur 6 12 month conventional chemotherapy-based platinum salt .</brief_summary>
	<brief_title>Trial High Dose Topotecan With Carboplatin Patients With Relapsed Ovarian Carcinoma</brief_title>
	<detailed_description>The combination Topotecan plus carboplatin high dos publish Miles Prince et al 2001 . In triple combination , author able define Maximum Tolerated Dose ( MTD ) 3.5 mg / m² / day x 5 day topotecan , 250 mg / m² paclitaxel AUC 12 carboplatin ( 46 ) . The MTD topotecan combine carboplatin ( AUC 16 ) VP 16 could determine Carroll et al ( 47 ) . However , study ITOV01bis ( ASCO abstract 2007 No . 1661 ) , MTD topotecan determine combination cyclophosphamide 120 mg / kg fixed 9 mg/m2/jx 5 day , DMT use monotherapy ITOV 01 ) . Studies relate , combination high dose topotecan carboplatin seem possible limited dose carboplatin AUC 20 , allocation 5 day drug [ fix daily AUC 4 carboplatin , program TAXIF I germ cell tumor , publish team ( Annual Oncology 2004 ) well TAXIF II develop Tenon 's hospital ] administration time 30 minute daily topotecan 2 hour carboplatin . data justify pattern study : - establish treatment 5 consecutive day provide best therapeutic index , - infusion 30 minute , seem give less non-haematological toxicity compare continuous infusion , prevail trial ITOV 01 , - Rescue blood stem cell ( collect chemotherapy mobilization-type high-dose cyclophosphamide follow hematopoietic growth factor ( G-CSF , Filgrastim ) reinjection schedule H96 treatment end , - six sequential dos establish absence limit toxicity , follow : 7.5 - 8.0 - 8.5 - 9.0 - 9.5 - 10.0 mg/m2 . Steps 9.5 mg / m² 10 mg / discuss approval independent committee charge studyContinuation Topotecan conventional dose do thanks clinical data base efficacy tolerance</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Primary ovarian tubal adenocarcinoma , peritoneal carcinoma histologically prove Age 18 65 ECOG criterion £ 2 Patients first relapse ovarian carcinoma without platinumtreatment since 612 month firstline therapy platinum salt taxanes together successively Negative viral serology ( HbS , HbC HIV ) Informed consent Patients social security Refractory ( relapse &lt; 6 month ) sensitive ( relapse &gt; 12 month ) relapse ovarian carcinoma Life expectancy &lt; 3 month Previous treatment pelvic radiography Previous treatment Topotecan topoisomer I inhibitor Non resolutive intestinal obstruction symptomatic treatment Creatinine &gt; equal 1.25N and/or creatinine clearance &lt; equal 60 ml/mn Bilirubin &gt; 1.25N ; transaminase alkaline phosphatase &gt; 2N ( 3N hepatic metastasis present ) Abnormal heart ( ultrasound ) ( FR &lt; 30 % ; FEVG &lt; 50 % ) White blood cell &lt; equal 4.0 x 109/L , Neutrophils &lt; equal 1.5 x 109/L , platelet &lt; equal 100 x 109/L Neuropathy : grade &gt; equal 2 Epilepsy Symptomatic cerebral metastasis Serious psychiatric pathology Uncontrolled serious infection Patient already receive peripheral blood stem cell support Haematopoeitic growth factor allergy More one line chemotherapy Impossibility use central veinous access Hypersensibility carboplatin platinum contain product Participation clinical trial Absence effective contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Carboplatine</keyword>
	<keyword>Higt dose chemotherapy</keyword>
</DOC>